24
Participants
Start Date
June 1, 2022
Primary Completion Date
November 30, 2025
Study Completion Date
May 31, 2028
Cabozantinib
Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
RECRUITING
Miami Cancer Institute at Baptist Health, Inc., Miami
RECRUITING
Vanderbilt University Medical Center, Nashville
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
Collaborators (1)
Exelixis
INDUSTRY
Baptist Health South Florida
OTHER